Literature DB >> 12457392

Clinical characteristics of adolescents later hospitalized for schizophrenia.

Mark Weiser1, Haim Y Knobler, Shlomo Noy, Zeev Kaplan.   

Abstract

Intellectual and behavioral abnormalities, non-psychotic psychiatric disorders, and drug abuse are sometimes present in adolescents who later develop schizophrenia. We followed a population-based cohort of adolescents with baseline assessments of intellectual and behavioral functioning, non-psychotic psychiatric disorders and drug abuse, and ascertained future hospitalization for schizophrenia. Results of the medical and mental health assessments on 16- to 17-year-old male adolescents screened by the Israeli Draft Board, were cross-linked with the National Psychiatric Hospitalization Case Registry, which contains data on all psychiatric hospitalizations in the country. Male adolescents who were later hospitalized for schizophrenia had significantly poorer test scores on all measures in comparison with adolescents not reported to the Psychiatric Registry, the magnitude of the differences was 0.3-0.5 standard deviation (SD). Adolescents (1.03%) of assigned a non-psychotic psychiatric diagnosis, compared to of the adolescents without any psychiatric diagnosis (0.23%), were later hospitalized for schizophrenia. Patients with schizophrenia (26.8%), compared to only 7.4% in the general population of adolescents, had been assigned a non-psychotic psychiatric diagnosis in adolescence (overall OR = 4.5, 95% CI = 3.6-5.6), ranging from OR = 21.5, (<2 >95% CI = 12.6-36.6) for schizophrenia-spectrum personality disorders to OR = 3.6 (<2 >95% CI = 2.1-6.2) for neurosis. The prevalence of self-reported drug abuse was higher in adolescents later hospitalized for schizophrenia (12.4%), compared to the prevalence of drug abuse in adolescents not later hospitalized (5.9%); adjusted RR = 2.033, 95% CI = 1.322-3.126. These results reflect the relatively common finding of impaired intellectual and behavioral functioning, the presence of non-psychotic psychiatric disorders, and drug abuse, in adolescents later hospitalized for schizophrenia, together with the relatively low power of these disorders in predicting schizophrenia. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12457392     DOI: 10.1002/ajmg.10647

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  19 in total

1.  Genetic and Environmental Contributions to the Association Between Cannabis Use and Psychotic-Like Experiences in Young Adult Twins.

Authors:  Ragnar Nesvåg; Ted Reichborn-Kjennerud; Nathan A Gillespie; Gun Peggy Knudsen; Jørgen G Bramness; Kenneth S Kendler; Eivind Ystrom
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

2.  l-Theanine Prevents Long-Term Affective and Cognitive Side Effects of Adolescent Δ-9-Tetrahydrocannabinol Exposure and Blocks Associated Molecular and Neuronal Abnormalities in the Mesocorticolimbic Circuitry.

Authors:  Marta De Felice; Justine Renard; Roger Hudson; Hanna J Szkudlarek; Brian J Pereira; Susanne Schmid; Walter J Rushlow; Steven R Laviolette
Journal:  J Neurosci       Date:  2020-12-02       Impact factor: 6.167

3.  Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.

Authors:  Serge Sevy; Delbert G Robinson; Barbara Napolitano; Raman C Patel; Handan Gunduz-Bruce; Rachel Miller; Joanne McCormack; Beth S Lorell; John Kane
Journal:  Schizophr Res       Date:  2010-05-14       Impact factor: 4.939

4.  The interplay of childhood behavior problems and IQ in the development of later schizophrenia and affective psychoses.

Authors:  Jessica Agnew-Blais; Larry J Seidman; Garrett M Fitzmaurice; Jordan W Smoller; Jill M Goldstein; Stephen L Buka
Journal:  Schizophr Res       Date:  2017-01-03       Impact factor: 4.939

5.  Cannabis use disorders in schizophrenia: effects on cognition and symptoms.

Authors:  Pamela DeRosse; Alyson Kaplan; Katherine E Burdick; Todd Lencz; Anil K Malhotra
Journal:  Schizophr Res       Date:  2010-05-18       Impact factor: 4.939

6.  (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population.

Authors:  Isabel Martínez-Gras; Janet Hoenicka; Guillermo Ponce; Roberto Rodríguez-Jiménez; Miguel Angel Jiménez-Arriero; Elena Pérez-Hernandez; Israel Ampuero; Jose Antonio Ramos-Atance; Tomas Palomo; Gabriel Rubio
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-20       Impact factor: 5.270

7.  Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients.

Authors:  Yoram Braw; Yuval Bloch; Shlomo Mendelovich; Gideon Ratzoni; Gilad Gal; Hagai Harari; Asaf Tripto; Yechiel Levkovitz
Journal:  Schizophr Bull       Date:  2007-11-05       Impact factor: 9.306

8.  Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia.

Authors:  Christoph U Correll; Christopher W Smith; Andrea M Auther; Danielle McLaughlin; Manoj Shah; Carmel Foley; Ruth Olsen; Todd Lencz; John M Kane; Barbara A Cornblatt
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-10       Impact factor: 2.576

9.  Early intervention in psychosis: concepts, evidence and future directions.

Authors:  Patrick D McGorry; Eóin Killackey; Alison Yung
Journal:  World Psychiatry       Date:  2008-10       Impact factor: 49.548

10.  Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.

Authors:  Robin M Murray; Harriet Quigley; Diego Quattrone; Amir Englund; Marta Di Forti
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.